# Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

> **NCT00098293** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 916 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** Maraviroc + Zidovudine/Lamivudine
- **DRUG:** Efavirenz + Zidovudine/Lamivudine
- **DRUG:** Maraviroc (UK-427,857) + Zidovudine/Lamivudine

## Key facts

- **NCT ID:** NCT00098293
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2007-04
- **Final completion:** 2012-12
- **Target enrollment:** 916 (ACTUAL)
- **Last updated:** 2013-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098293, "Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00098293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*